person · Reporting owner
Murray Lilian Shackelford
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcadia Biosciences, Inc.RKDA · Entity 8593 | Director | September 10, 2026 | September 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcadia Biosciences, Inc.
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2036-09-10 | Direct | 23,287 |
Reported balance
After 2026-09-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-10 · Grant · Acquired 10,000 · Balance 23,287 F1: The Option will become 100% vested and exercisable on the earlier to occur of (i) September 10, 2027 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The Option will become 100% vested and exercisable on the earlier to occur of (i) September 10, 2027 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 14, 2026 20:01 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001193125-26-390520 · ownership.xml · derivative · entry 1 Murray Lilian Shackelford · CIK 0001743173 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,287 Underlying: Common Stock · 10,000 shares Expires 2036-09-10 F1 · derivative.exercise_date: The Option will become 100% vested and exercisable on the earlier to occur of (i) September 10, 2027 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 23:26 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (Right to Buy) · Derivative | 10,909 | $0.00 Strike: $2.71 | $0.00 |
DisclosureSEC source: 0000950170-24-099625 · ownership.xml · derivative · entry 1 Murray Lilian Shackelford · CIK 0001743173 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,287 Underlying: Common Stock · 10,909 shares Expires 2034-08-19 F1 · derivative.exercise_date: The Option will become 100% vested and exercisable on the earlier to occur of (i) August 19, 2025 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service. Read SEC document |
| June 06, 2023 Filed Jun 16, 2023 16:51 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (Right to Buy) · Derivative | 937 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-23-037750 · doc4.xml · derivative · entry 1 Murray Lilian Shackelford · CIK 0001743173 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,378 Underlying: Common Stock · 937 shares Expires 2033-06-06 F1 · derivative.exercise_date: The Option will become 100% vested and exercisable on the earlier to occur of (i) June 6, 2024 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:44 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 23,620 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001209191-22-034108 · doc4.xml · derivative · entry 1 Murray Lilian Shackelford · CIK 0001743173 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,765 Underlying: Common Stock · 23,620 shares Expires 2032-06-01 F1 · derivative.exercise_date: The Option will become 100% vested and exercisable on the earlier to occur of (i) June 1, 2023 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:14 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 10,935 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001209191-21-038203 · doc4.xml · derivative · entry 1 Murray Lilian Shackelford · CIK 0001743173 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,145 Underlying: Common Stock · 10,935 shares Expires 2031-06-02 F1 · derivative.exercise_date: The Option will become 100% vested and exercisable on the earlier to occur of (i) June 2, 2022 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 17:19 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 753 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0001209191-20-042124 · doc4.xml · derivative · entry 1 Murray Lilian Shackelford · CIK 0001743173 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,210 Underlying: Common Stock · 753 shares Expires 2030-07-08 F1 · date: The Option will become 100% vested and exercisable on July 8, 2021. F1 · derivative.exercise_date: The Option will become 100% vested and exercisable on July 8, 2021. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 15:12 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 9,137 | $0.00 Strike: $3.69 | $0.00 |
DisclosureSEC source: 0001209191-20-033827 · doc4.xml · derivative · entry 1 Murray Lilian Shackelford · CIK 0001743173 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,457 Underlying: Common Stock · 9,137 shares Expires 2030-06-01 F1 · derivative.exercise_date: The Option will become 100% vested and exercisable on the earlier to occur of (i) June 1, 2021 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 15:50 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon stock | 5,000 | $4.25 | $21,250.00 |
DisclosureSEC source: 0001209191-19-057084 · doc4.xml · nonDerivative · entry 1 Murray Lilian Shackelford · CIK 0001743173 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,524 Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 23:51 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 6,912 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-19-034585 · doc4.xml · derivative · entry 1 Murray Lilian Shackelford · CIK 0001743173 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,320 Underlying: Common Stock · 6,912 shares Expires 2029-06-03 F1 · derivative.exercise_date: The Option will become 100% vested and exercisable on the earlier to occur of (i) June 3, 2020 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 23:56 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantCommon Stock (right to buy) · Derivative | 6,408 | $0.00 Strike: $10.80 | $0.00 |
DisclosureSEC source: 0001209191-18-036806 · doc4.xml · derivative · entry 1 Murray Lilian Shackelford · CIK 0001743173 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,408 Underlying: Common Stock · 6,408 shares Expires 2028-06-06 F1 · derivative.exercise_date: The option vests in three equal installments occurring on the first, second and third anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.